Loading in 2 Seconds...
Loading in 2 Seconds...
Wilson’s Disease Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/wilsons-disease-drugs-market
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
The latest market report published by Credence Research, Inc. “Wilson’s Disease
Drugs Market - Growth, Future Prospects, Competitive Analysis, 2017 -
2025,” the global Wilson’s disease drugs market was valued at US$ 372.5 Mn in 2016, and
is expected to reach US$ 592.8 Mn by 2025 expanding at a CAGR of 5.19 % from 2017 to
Pharmaceutical manufacturers are currently focusing in addressing the abnormal copper
metabolism to prevent the excessive deposition of copper in liver and other body organs.
WTX101 also known as bis-choline tetrathiomolybdenate developed by Wilson
Therapeutics AB is showing promising results in the phase 3 clinical trial study for
treatment of Wilson’s disease. It is the first novel copper protein binding agent with
unique mechanism of action. WTX101 has high specificity for copper and forms copper
protein complexes and provides alternative mechanism for the transport of copper
protein transport. Excessive copper levels are reduced in the blood and liver cells and
promotes biliary excretion of copper. Gene therapy is also a feasible option which will
transport functional ATPB7 gene via gene vectors.
Browse the full report Wilson’s Disease Drugs Market - Growth, Future Prospects,
Chelators are the first line of treatment for disease management of Wilson’s disease. They
prevent the excessive deposition of copper in liver cells by expediting urine excretion of
copper. Zinc is used in patients non-reactive to chelators therapy. It has less adverse
events and used in long term therapy of Wilson’s disease.
The hepatic conditions are first diagnosed in patients suffering with Wilson’s disease due
to large accumulation of copper in the liver cells causing an increase in aspartate
aminotransferase and alanine aminotransferase. Neuropsychiatric symptoms are
manifested in the later stages of the disease with patient showing symptoms of seizures,
ataxia and tremors.
North America currently enjoys the leading position in Wilson’s disease treatment drugs
market on account of rising prevalence of Wilson’s disease in Caucasian population and
supportive regulatory environment provided by the USFDA for drugs employed in
treatment of Wilson’s disease. Recent technological advancement in laboratory
diagnostics in Asia Pacific has resulted in accurate diagnosis of patients suffering with
Wilson’s disease. Asia Pacific has tremendous opportunity for its established generic
market to manufacture drugs which are otherwise imported from western countries.
The pharmaceutical companies proactive in the treatment of Wilson’s disease are
Kadmon Holdings, Inc., Valeant Pharmaceuticals International, Inc., Merck & Co., Noble
Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., VHB Life
Sciences, Inc. and Wilson Therapeutics AB.
Accurate diagnosis of symptoms has brought enormous patients suffering with
Wilson’s disease in drug treatment regimen
Orphan disease status has acquired supportive regulatory milieu for the novel drug
discovery and development of Wilson’s disease
Enormous opportunity for major pharma players to conduct clinical trials and
establish R&D centers in developing nations with unmet medical needs
Table of Content
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Wilson’s Disease Treatment Drugs Market Portraiture
2.1.1. Global Wilson’s Disease Treatment Drugs Market, by Indication, 2016 (Value
2.1.2. Global Wilson’s Disease Treatment Drugs Market, by Drug Class, 2016
2.1.3. Global Wilson’s Disease Treatment Drugs Market, by Geography, 2016
Chapter 3. Wilson’s Disease Treatment Drugs Market: Dynamics and
3.1. Market Overview
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Wilson’s Disease Drugs Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape : Global Wilson’s Disease Drugs Market, by Key
Players, 2015-2025 (US$ Mn)
Chapter 4. Global Wilson’s Disease Drugs Market, by Indication, 2015
– 2025 (US$ Mn)
4.2. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by
4.6. Others (Heart and Kidney Complications)
Chapter 5. Global Wilson’s Disease Drugs Market, by Drug Class, 2015
– 2025 (US$ Mn)
5.1.1. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market,
by Drug Class, 2016
Credence Research is a worldwide market research and counseling firm that serves
driving organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to their
execution and understand their most imperative objectives. Over almost a century, we’ve
manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith